Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:BIIB
- CUSIP: 09062X10
- Web: www.biogen.com
Capitalization:- Market Cap: $67.33254 billion
- Outstanding Shares: 211,431,000
Average Prices:- 50 Day Moving Avg: $300.47
- 200 Day Moving Avg: $278.47
- 52 Week Range: $244.28 - $330.00
P/E:- Trailing P/E Ratio: 20.90
- Foreward P/E Ratio: 13.76
- P/E Growth: 2.24
Sales & Book Value:- Annual Revenue: $11.72 billion
- Price / Sales: 5.75
- Book Value: $54.79 per share
- Price / Book: 5.81
Profitability:- EBIDTA: $6.42 billion
- Net Margins: 28.10%
- Return on Equity: 37.42%
- Return on Assets: 20.12%
Debt:- Debt-to-Equity Ratio: 0.51%
- Current Ratio: 2.10%
- Quick Ratio: 1.83%
Misc:- Average Volume: 1.36 million shs.
- Beta: 0.77
- Short Ratio: 2.28
Frequently Asked Questions for Biogen (NASDAQ:BIIB)
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen Inc. (NASDAQ:BIIB) released its earnings results on Tuesday, July, 25th. The company reported $5.04 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $4.36 by $0.68. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The firm's quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the firm earned $5.21 EPS. View Biogen's Earnings History.
When will Biogen make its next earnings announcement?
What guidance has Biogen issued on next quarter's earnings?
Biogen issued an update on its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share guidance of $20.80-21.40 for the period, compared to the Thomson Reuters consensus estimate of $20.37. The company issued revenue guidance of $11.5-11.8 billion, compared to the consensus revenue estimate of $11.40 billion.
Where is Biogen's stock going? Where will Biogen's stock price be in 2017?
24 brokers have issued 1 year price targets for Biogen's stock. Their forecasts range from $271.00 to $442.00. On average, they expect Biogen's share price to reach $329.27 in the next twelve months. View Analyst Ratings for Biogen.
What are analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. Cantor Fitzgerald analysts commented, "A German patient treated for three years with Tysabri and then with a single dose of Ocrevus developed PML." (5/25/2017)
- 2. Cowen and Company analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
- 3. Mizuho analysts commented, "We just started our Spinraza webinar … here’s a link to the slides pdf Rating Neutral Previous Rating No Change Price (4/17) $274.05 Price Target $290.00 Previous Price Target No Change LINK to slides for our Spinraza webinar (for folks who prefer a pdf copy): CLICK HERE Link to join webinar (just started): CLICK HERE We intend to blast a replay of the webinar after we finish. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (4/18/2017)
- 4. Instinet analysts commented, "We are initiating on BIIB with a Buy rating and $345 target price. We recommend owning BIIB shares over the next 12 months given limited 2017 downside to revenue forecasts and potential Spinraza launch upside. We estimate that a successful Spinraza launch will drive above-consensus revenues of $11.6bn in 2017 and $12.2bn in 2018, despite flat MS-franchise growth that may be impacted by emerging competition (Ocrevus). We anticipate this return to growth will drive modest revenue multiple expansion and strong GAAP EPS growth - to $19.41 in 2017 and $21.56 in 2018, yielding upside to our $345 target price." (3/1/2017)
- 5. Jefferies Group LLC analysts commented, "This morning BIIB announced a settlement with FWP around Tecfidera IP. While we believe Street expectations were generally balanced going into the 3/17 decision (and we had assumed 50/50 prob. BIIB would be successful), commercial and some IPR risk remains, and recent focus has been more on Spinraza launch and Alzheimer’s, the terms look reasonable to us and help reduce an overhang." (1/18/2017)
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), Sinovac Biotech (SVA), Syros Pharmaceuticals (SYRS), ChemoCentryx (CCXI), Mirna Therapeutics (SYBX), Strongbridge Biopharma PLC (SBBP), Syndax Pharmaceuticals (SNDX), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), Kadmon Holdings (KDMN), Kamada (KMDA), Vericel Corporation (VCEL), Peregrine Pharmaceuticals (PPHM) and MediWound (MDWD).
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board
- Michel Vounatsos, Chief Executive Officer, Director
- Gregory F. Covino, Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance
- Ginger Gregory Ph.D., Chief Human Resource Officer, Executive Vice President
- Kenneth A. Di Pietro, Executive Vice President - Human Resources
- Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary
- Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development
- Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs
- Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations
- Paul McKenzie Ph.D., Executive Vice President - Pharmaceutical Operations & Technology
Who owns Biogen stock?
Biogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.56%), Vanguard Group Inc. (6.87%), State Street Corp (4.60%), FMR LLC (2.89%), Northern Trust Corp (1.43%) and Alliancebernstein L.P. (1.14%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.
Who sold Biogen stock? Who is selling Biogen stock?
Biogen's stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Winslow Capital Management LLC, Alliancebernstein L.P., Franklin Resources Inc., PointState Capital LP, Ameriprise Financial Inc., Bank of New York Mellon Corp and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Biogen stock in the last year include Adriana Karaboutis, Alfred Sandrock, Brian S Posner, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.
Who bought Biogen stock? Who is buying Biogen stock?
Biogen's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Manning & Napier Advisors LLC, FMR LLC, TIAA CREF Investment Management LLC, BlackRock Inc., LSV Asset Management, Parametric Portfolio Associates LLC and Samlyn Capital LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.
How do I buy Biogen stock?
Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of Biogen stock can currently be purchased for approximately $318.46.
MarketBeat Community Rating for Biogen (NASDAQ BIIB)MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Biogen (NASDAQ:BIIB) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 12 Hold Ratings, 11 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.54) |
| Consensus Price Target: | $329.27 (3.40% upside) |
Analysts' Ratings History for Biogen (NASDAQ:BIIB)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/21/2017 | Raymond James Financial, Inc. | Downgrade | Strong-Buy -> Market Perform | $244.28 -> $319.00 | Low |  |
| 9/20/2017 | SunTrust Banks, Inc. | Initiated Coverage | Buy -> Buy | $360.00 | Low | |
| 9/14/2017 | Royal Bank Of Canada | Initiated Coverage | Sector Perform -> Sector Perform | $319.00 | Medium | |
| 9/13/2017 | BMO Capital Markets | Boost Price Target | Market Perform | $328.00 -> $377.00 | Low | |
| 9/13/2017 | Mizuho | Reiterated Rating | Neutral | $274.00 -> $319.00 | Medium | |
| 8/25/2017 | Robert W. Baird | Reiterated Rating | Hold | $290.00 | Low | |
| 8/16/2017 | Goldman Sachs Group, Inc. (The) | Upgrade | Buy -> Conviction-Buy | $338.00 | Low | |
| 7/27/2017 | Cowen and Company | Reiterated Rating | Buy | | Medium | |
| 7/26/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $301.00 -> $311.00 | Low | |
| 7/26/2017 | Deutsche Bank AG | Reiterated Rating | Buy | $315.00 -> $319.00 | Low | |
| 7/26/2017 | Leerink Swann | Reiterated Rating | Market Perform | $304.00 -> $338.00 | High | |
| 7/14/2017 | Credit Suisse Group | Set Price Target | Hold | $300.00 | Low | |
| 7/11/2017 | Jefferies Group LLC | Reiterated Rating | Hold -> Hold | $310.00 | Low | |
| 6/26/2017 | William Blair | Reiterated Rating | Outperform | | High | |
| 5/25/2017 | Sanford C. Bernstein | Reiterated Rating | Outperform | | Low | |
| 5/25/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $277.00 | Low | |
| 5/15/2017 | Piper Jaffray Companies | Set Price Target | Buy | $332.00 -> $442.00 | Low | |
| 4/26/2017 | Stifel Nicolaus | Boost Price Target | Hold | $265.00 -> $280.00 | Medium | |
| 4/23/2017 | Barclays PLC | Reiterated Rating | Overweight | $380.00 -> $360.00 | Medium | |
| 4/4/2017 | Citigroup Inc. | Boost Price Target | Buy | $305.00 -> $315.00 | Low | |
| 3/1/2017 | Instinet | Initiated Coverage | Buy -> Buy | $223.03 -> $345.00 | N/A | |
| 3/1/2017 | Nomura | Initiated Coverage | Neutral | | N/A | |
| 1/30/2017 | HC Wainwright | Reiterated Rating | Buy | $360.00 | N/A | |
| 1/18/2017 | J P Morgan Chase & Co | Reiterated Rating | Buy | | N/A | |
| 9/22/2016 | Bank of America Corporation | Reiterated Rating | Buy | $374.00 | N/A | |
| 8/2/2016 | Standpoint Research | Downgrade | Buy -> Hold | | N/A | |
| 6/8/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 12/18/2015 | Atlantic Securities | Initiated Coverage | Overweight | $344.00 | N/A | |
(Data available from 9/25/2015 forward)
Earnings History for Biogen (NASDAQ:BIIB)Earnings History by Quarter for Biogen (NASDAQ BIIB)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | $5.61 | | | | | N/A | |
| 7/25/2017 | Q2 2017 | $4.36 | $5.04 | $2.81 billion | $3.08 billion | View | N/A | |
| 4/25/2017 | Q1 2017 | $4.97 | $5.20 | $2.73 billion | $2.81 billion | View | N/A | |
| 1/26/2017 | Q416 | $4.96 | $5.04 | $2.94 billion | $2.87 billion | View | N/A | |
| 10/26/2016 | Q316 | $4.97 | $5.19 | $2.91 billion | $2.96 billion | View | Listen | |
| 7/21/2016 | Q216 | $4.69 | $5.21 | $2.79 billion | $2.89 billion | View | Listen | |
| 4/21/2016 | Q116 | $4.47 | $4.79 | $2.75 billion | $2.73 billion | View | Listen | |
| 1/27/2016 | Q415 | $4.08 | $4.50 | $2.70 billion | $2.84 billion | View | Listen | |
| 10/21/2015 | Q315 | $3.80 | $4.48 | $2.65 billion | $2.39 billion | View | Listen | |
| 7/24/2015 | Q215 | $4.10 | $4.22 | $2.71 billion | $2.59 billion | View | Listen | |
| 4/24/2015 | Q115 | $3.91 | $3.82 | $2.66 billion | $2.56 billion | View | Listen | |
| 1/29/2015 | Q414 | $3.74 | $4.09 | $2.64 billion | $2.60 billion | View | Listen | |
| 10/22/2014 | Q3 | $3.22 | $3.80 | $2.48 billion | $2.50 billion | View | Listen | |
| 7/23/2014 | Q214 | $2.80 | $3.49 | $2.14 billion | $2.42 billion | View | Listen | |
| 4/23/2014 | Q114 | $2.56 | $2.47 | $2.00 billion | $2.10 billion | View | Listen | |
| 1/29/2014 | Q413 | $2.27 | $2.34 | $1.93 billion | $2.00 billion | View | Listen | |
| 10/28/2013 | Q313 | $2.10 | $2.35 | $1.78 billion | $1.83 billion | View | Listen | |
| 7/25/2013 | Q2 2013 | $1.93 | $2.30 | $1.62 billion | $1.70 billion | View | Listen | |
| 4/25/2013 | Q1 2013 | $1.63 | $1.97 | $1.41 billion | $1.40 billion | View | Listen | |
| 1/28/2013 | Q4 2012 | $1.46 | $1.40 | $1.38 billion | $1.40 billion | View | Listen | |
| 10/25/2012 | | $1.60 | $1.91 | | | View | N/A | |
| 7/24/2012 | | $1.56 | $1.82 | | | View | N/A | |
| 5/1/2012 | | $1.49 | $1.40 | | | View | N/A | |
| 1/31/2012 | | $1.49 | $1.51 | | | View | N/A | |
| 10/28/2011 | | $1.52 | $1.61 | | | View | N/A | |
| 7/26/2011 | | $1.36 | $1.36 | | | View | N/A | |
| 4/21/2011 | | $1.41 | $1.43 | | | View | N/A | |
| 2/1/2011 | | $1.23 | $1.42 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Biogen (NASDAQ:BIIB)2017 EPS Consensus Estimate: $20.36
2018 EPS Consensus Estimate: $24.24
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $4.47 | $5.03 | $4.75 |
| Q2 2017 | 3 | $3.92 | $4.11 | $4.04 |
| Q3 2017 | 4 | $5.69 | $6.16 | $5.92 |
| Q4 2017 | 5 | $4.94 | $6.05 | $5.65 |
| Q1 2018 | 2 | $5.70 | $5.88 | $5.79 |
| Q2 2018 | 2 | $5.95 | $6.22 | $6.09 |
| Q3 2018 | 2 | $6.11 | $6.17 | $6.14 |
| Q4 2018 | 2 | $6.20 | $6.24 | $6.22 |
| Q1 2019 | 1 | $6.30 | $6.30 | $6.30 |
| Q2 2019 | 1 | $6.53 | $6.53 | $6.53 |
(Data provided by Zacks Investment Research)
Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biogen (NASDAQ:BIIB)Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 87.65%
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/25/2017 | Susan H Alexander | EVP | Sell | 4,974 | $290.01 | $1,442,509.74 | |
| 7/19/2017 | Susan H Alexander | EVP | Sell | 7,758 | $285.00 | $2,211,030.00 | |
| 6/9/2017 | Brian S Posner | Director | Sell | 1,084 | $256.31 | $277,840.04 | |
| 5/1/2017 | Michel Vounatsos | CEO | Buy | 1,402 | $271.35 | $380,432.70 | |
| 4/27/2017 | Alexander J. Denner | Director | Buy | 73,858 | $278.50 | $20,569,453.00 | |
| 4/25/2017 | Paul J Clancy | VP | Sell | 9,892 | $290.00 | $2,868,680.00 | |
| 4/3/2017 | Alfred Sandrock | CMO | Sell | 1,981 | $274.08 | $542,952.48 | |
| 3/13/2017 | Paul J Clancy | VP | Sell | 9,891 | $291.55 | $2,883,721.05 | |
| 2/27/2017 | Michel Vounatsos | CEO | Buy | 1,333 | $285.39 | $380,424.87 | |
| 1/9/2017 | Robert W Pangia | Director | Sell | 5,450 | $295.39 | $1,609,875.50 | |
| 10/4/2016 | Adriana Karaboutis | EVP | Sell | 262 | $311.94 | $81,728.28 | |
| 10/3/2016 | Adriana Karaboutis | EVP | Sell | 380 | $313.00 | $118,940.00 | |
| 9/22/2016 | Caroline Dorsa | Director | Sell | 27,570 | $314.00 | $8,656,980.00 | |
| 7/21/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | |
| 6/6/2016 | Adam Koppel | EVP | Sell | 555 | $290.00 | $160,950.00 | |
| 6/3/2016 | George A Scangos | CEO | Sell | 842 | $290.00 | $244,180.00 | |
| 6/1/2016 | George A Scangos | CEO | Sell | 3,855 | $289.74 | $1,116,947.70 | |
| 5/25/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | |
| 5/2/2016 | George A Scangos | CEO | Sell | 487 | $274.74 | $133,798.38 | |
| 4/6/2016 | Adam Koppel | EVP | Sell | 102 | $275.00 | $28,050.00 | |
| 4/6/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | |
| 4/1/2016 | George A Scangos | CEO | Sell | 487 | $258.83 | $126,050.21 | |
| 3/1/2016 | George A Scangos | CEO | Sell | 487 | $261.37 | $127,287.19 | |
| 2/25/2016 | Adriana Karaboutis | EVP | Sell | 84 | $261.90 | $21,999.60 | |
| 2/25/2016 | Alfred Sandrock | CMO | Sell | 183 | $261.90 | $47,927.70 | |
| 2/17/2016 | Alfred Sandrock | Chief Medical Officer | Sell | 722 | $256.16 | $184,947.52 | |
| 2/17/2016 | George A Scangos | CEO | Sell | 487 | $256.16 | $124,749.92 | |
| 2/9/2016 | Alfred Sandrock | Chief Medical Officer | Sell | 852 | $246.54 | $210,052.08 | |
| 12/4/2015 | Alfred Sandrock | CMO | Sell | 441 | $277.00 | $122,157.00 | |
| 10/23/2015 | Alexander J Denner | Director | Buy | 310,000 | $277.47 | $86,015,700.00 | |
| 7/27/2015 | Stelios Papadopoulos | Director | Buy | 10,000 | $304.88 | $3,048,800.00 | |
| 6/19/2015 | Douglas E Williams | EVP | Sell | 3,841 | $410.00 | $1,574,810.00 | |
| 6/1/2015 | George A Scangos | CEO | Sell | 1,362 | $398.87 | $543,260.94 | |
| 4/1/2015 | George A Scangos | CEO | Sell | 1,362 | $423.20 | $576,398.40 | |
| 3/25/2015 | John Cox | EVP | Sell | 12,010 | $449.06 | $5,393,210.60 | |
| 3/20/2015 | Eric K Rowinsky | Director | Sell | 11,667 | $475.00 | $5,541,825.00 | |
| 3/19/2015 | Eric K Rowinsky | Director | Sell | 2,333 | $436.14 | $1,017,514.62 | |
| 3/17/2015 | Eric K Rowinsky | Director | Sell | 4,667 | $425.45 | $1,985,575.15 | |
| 3/10/2015 | Robert W Pangia | Director | Sell | 3,625 | $413.40 | $1,498,575.00 | |
| 3/2/2015 | Alfred Sandrock | SVP | Sell | 3,174 | $409.49 | $1,299,721.26 | |
| 2/17/2015 | Steven H Holtzman | EVP | Sell | 2,128 | $389.11 | $828,026.08 | |
| 2/10/2015 | Alfred Sandrock | SVP | Sell | 1,143 | $398.11 | $455,039.73 | |
| 2/2/2015 | Kenneth Dipietro | EVP | Sell | 1,656 | $389.03 | $644,233.68 | |
| 12/15/2014 | Spyridon Artavanis-Tsakonas | SVP | Sell | 1,981 | $346.50 | $686,416.50 | |
| 12/2/2014 | Steven H Holtzman | EVP | Sell | 1,749 | $335.65 | $587,051.85 | |
| 11/11/2014 | Steven H Holtzman | EVP | Sell | 1,750 | $330.00 | $577,500.00 | |
| 11/3/2014 | George A Scangos | CEO | Sell | 1,128 | $320.78 | $361,839.84 | |
| 10/1/2014 | George A Scangos | CEO | Sell | 1,127 | $330.97 | $373,003.19 | |
| 10/1/2014 | Steven H Holtzman | EVP | Sell | 1,750 | $330.97 | $579,197.50 | |
| 8/1/2014 | George A Scangos | CEO | Sell | 1,128 | $332.93 | $375,545.04 | |
| 7/16/2014 | George A Scangos | CEO | Sell | 12,316 | $312.37 | $3,847,148.92 | |
| 5/19/2014 | Steven Holtzman | EVP | Sell | 1,221 | $289.15 | $353,052.15 | |
| 5/1/2014 | George Scangos | CEO | Sell | 2,123 | $285.56 | $606,243.88 | |
| 4/17/2014 | Steven Holtzman | EVP | Sell | 1,221 | $291.00 | $355,311.00 | |
| 4/1/2014 | George Scangos | CEO | Sell | 2,123 | $308.42 | $654,775.66 | |
| 4/1/2014 | Robert Pangia | Director | Sell | 6,250 | $308.42 | $1,927,625.00 | |
| 3/31/2014 | Brian Posner | Director | Sell | 3,000 | $296.76 | $890,280.00 | |
| 3/20/2014 | Caroline Dorsa | Director | Sell | 10,000 | $348.88 | $3,488,800.00 | |
| 3/19/2014 | Douglas Williams | EVP | Sell | 3,505 | $352.29 | $1,234,776.45 | |
| 3/17/2014 | Steven Holtzman | EVP | Sell | 1,221 | $334.83 | $408,827.43 | |
| 3/11/2014 | Stuart Kingsley | EVP | Sell | 8,428 | $336.83 | $2,838,803.24 | |
| 3/3/2014 | George Scangos | CEO | Sell | 2,942 | $335.79 | $987,894.18 | |
| 2/26/2014 | Alfred Sandrock | SVP | Sell | 1,048 | $342.17 | $358,594.16 | |
| 2/18/2014 | Steven Holtzman | EVP | Sell | 1,222 | $327.90 | $400,693.80 | |
| 2/13/2014 | Kenneth Dipietro | EVP | Sell | 1,290 | $316.81 | $408,684.90 | |
| 2/11/2014 | Alfred Sandrock | SVP | Sell | 2,085 | $314.31 | $655,336.35 | |
| 2/11/2014 | George Scangos | CEO | Sell | 2,456 | $314.31 | $771,945.36 | |
| 2/4/2014 | Kenneth Dipietro | EVP | Sell | 1,655 | $299.01 | $494,861.55 | |
| 1/21/2014 | Eric Rowinsky | Director | Sell | 2,020 | $310.09 | $626,381.80 | |
| 1/15/2014 | Lynn Schenk | Director | Sell | 1,000 | $297.48 | $297,480.00 | |
| 1/8/2014 | William Young | Director | Sell | 15,000 | $285.11 | $4,276,650.00 | |
| 1/6/2014 | Robert Pangia | Director | Sell | 6,250 | $278.03 | $1,737,687.50 | |
| 12/2/2013 | Lynn Schenk | Director | Sell | 1,000 | $291.71 | $291,710.00 | |
| 11/22/2013 | Raymond Pawlicki | SVP | Sell | 4,000 | $288.00 | $1,152,000.00 | |
| 11/1/2013 | George A Scangos | CEO | Sell | 2,239 | $245.57 | $549,831.23 | |
| 11/1/2013 | Lynn Schenk | Director | Sell | 1,000 | $245.00 | $245,000.00 | |
| 10/22/2013 | Alfred Sandrock | SVP | Sell | 15,030 | $250.11 | $3,759,153.30 | |
| 9/18/2013 | Paul Clancy | CFO | Sell | 26,785 | $245.00 | $6,562,325.00 | |
| 9/17/2013 | Steven Holtzman | EVP | Sell | 3,501 | $238.98 | $836,668.98 | |
| 9/16/2013 | Paul Clancy | CFO | Sell | 99,030 | $238.27 | $23,595,878.10 | |
| 9/16/2013 | Raymond Pawlicki | SVP | Sell | 4,000 | $238.03 | $952,120.00 | |
| 9/3/2013 | George Scangos | CEO | Sell | 2,239 | $214.40 | $480,041.60 | |
| 8/26/2013 | Douglas Williams | EVP | Sell | 4,368 | $211.35 | $923,176.80 | |
| 8/1/2013 | George A Scangos | CEO | Sell | 2,239 | $218.82 | $489,937.98 | |
| 7/16/2013 | George A Scangos | CEO | Sell | 2,239 | $223.94 | $501,401.66 | |
| 6/14/2013 | Alexander J Denner | Director | Sell | 2,900 | $212.00 | $614,800.00 | |
| 6/11/2013 | Brian S Posner | Director | Sell | 2,020 | $219.62 | $443,632.40 | |
| 6/10/2013 | Lynn Schenk | Director | Sell | 2,000 | $225.82 | $451,640.00 | |
| 6/3/2013 | George A Scangos | CEO | Sell | 1,598 | $234.16 | $374,187.68 | |
| 6/3/2013 | Stephen A Sherwin | Director | Sell | 12,825 | $233.26 | $2,991,559.50 | |
| 5/28/2013 | Robert W Pangia | Director | Sell | 5,900 | $237.23 | $1,399,657.00 | |
| 12/27/2012 | Alexander J Denner | Director | Sell | 7,980 | $148.62 | $1,185,987.60 | |
(Data available from 1/1/2013 forward)
Headline Trends for Biogen (NASDAQ:BIIB)
Latest Headlines for Biogen (NASDAQ:BIIB)
| Source: |
|
| Date | Headline |
|---|
 | Head to Head Survey: Biogen (BIIB) and Its Peers
www.americanbankingnews.com - September 24 at 10:08 PM |
| Analyzing Cardiome Pharma Corporation (CRME) and Biogen (BIIB)
www.americanbankingnews.com - September 24 at 4:32 AM |
 | Biogen's stock falls after Raymond James cuts rating by two notches - MarketWatch
www.marketwatch.com - September 23 at 1:36 AM |
| Biogen Inc. (BIIB) Expected to Post Q3 2017 Earnings of $5.79 Per Share
www.americanbankingnews.com - September 22 at 6:56 AM |
| Biogen Inc. (BIIB) Cut to Market Perform at Raymond James Financial, Inc.
www.americanbankingnews.com - September 21 at 8:56 PM |
 | Biogen: Buy or Hold?
finance.yahoo.com - September 21 at 4:19 PM |
| Biogen Inc. (BIIB) Coverage Initiated by Analysts at SunTrust Banks, Inc.
www.americanbankingnews.com - September 20 at 9:46 AM |
 | Profit From the Biogen Inc (BIIB) Stock Dip! - Investorplace.com
investorplace.com - September 20 at 2:37 AM |
| Profit From the Biogen Inc (BIIB) Stock Dip!
investorplace.com - September 19 at 11:12 AM |
| Biogen Inc. (BIIB) Now Covered by Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 11:06 PM |
| Biogen Inc. (BIIB) Price Target Raised to $377.00
www.americanbankingnews.com - September 13 at 2:22 PM |
| Mizuho Reiterates "Neutral" Rating for Biogen Inc. (BIIB)
www.americanbankingnews.com - September 13 at 12:26 PM |
 | BIIB January 2020 Options Begin Trading - Nasdaq
www.nasdaq.com - September 12 at 4:49 PM |
| Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
finance.yahoo.com - September 12 at 4:49 PM |
| What Is Biogen Inc’s (BIIB) Share Price Doing?
finance.yahoo.com - September 12 at 4:49 PM |
| Biogen Reaches Analyst Target Price
www.nasdaq.com - September 11 at 5:13 PM |
| Biogen Inc. (BIIB) Stock Rating Upgraded by Vetr Inc.
www.americanbankingnews.com - September 9 at 11:22 PM |
| Brokerages Expect Biogen Inc. (BIIB) to Announce $5.61 Earnings Per Share
www.americanbankingnews.com - September 7 at 10:24 PM |
 | Why It's Useful To Know A Company's Competitors When Trading - Benzinga
www.benzinga.com - September 6 at 4:15 AM |
| Biogen (BIIB) vs. Peregrine Pharmaceuticals (PPHM) Head-To-Head Review
www.americanbankingnews.com - September 4 at 10:12 PM |
| Vetr Inc. Downgrades Biogen Inc. (BIIB) to Hold
www.americanbankingnews.com - September 4 at 1:16 PM |
| Biogen Inc. (BIIB) Cut to "Hold" at ValuEngine
www.americanbankingnews.com - September 3 at 9:00 PM |
| Biogen Inc. (BIIB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 2 at 2:38 PM |
 | Pro-Trader Daily: Featured Company News - Ionis Earns Regulatory Milestone Payment from Biogen for SPINRAZA
www.finanznachrichten.de - September 1 at 4:49 PM |
| These 4 Biotechs Just Moved Into Buy Zones; Is This Giant Next?
finance.yahoo.com - August 31 at 9:27 PM |
| Head-To-Head Review: Biogen (BIIB) & Baxalta (BXLT)
www.americanbankingnews.com - August 31 at 4:24 PM |
| Biogen's Alzheimer's Drug Shows Promise — Could It Break Out?
finance.yahoo.com - August 29 at 4:51 PM |
| Monday Sector Leaders: Healthcare, Technology & Communications - Nasdaq
www.nasdaq.com - August 28 at 9:36 PM |
| Biogen Inc. (BIIB) Rating Reiterated by Robert W. Baird
www.americanbankingnews.com - August 28 at 2:28 PM |
| FY2019 EPS Estimates for Biogen Inc. Boosted by William Blair (BIIB)
www.americanbankingnews.com - August 28 at 10:58 AM |
| Consider This Before You Buy Biogen
finance.yahoo.com - August 27 at 4:09 PM |
| Biogen's Humira Biosimilar Imraldi Gets Approval in EU - Yahoo Finance
finance.yahoo.com - August 26 at 4:13 PM |
 | ADMS Soars On FDA Nod, EARS Gets An Earful, Thumbs Up For BIIB's Humira Biosim
www.rttnews.com - August 25 at 5:01 AM |
| IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union
finance.yahoo.com - August 24 at 9:39 PM |
| Samsung, Biogen version of AbbVie's Humira approved in Europe
finance.yahoo.com - August 24 at 9:39 PM |
| Ionis Reports Revenue Growth in 2Q17
finance.yahoo.com - August 23 at 9:46 PM |
| Zacks: Analysts Anticipate Biogen Inc. (BIIB) Will Post Quarterly Sales of $3.00 Billion
www.americanbankingnews.com - August 22 at 3:46 PM |
| Biogen Inc. (BIIB) Lifted to "Conviction-Buy" at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - August 20 at 11:58 PM |
| Brokerages Expect Biogen Inc. (BIIB) to Announce $5.61 EPS
www.americanbankingnews.com - August 20 at 6:16 AM |
| Goldman has a new favorite biotech because of potential A...
finance.yahoo.com - August 18 at 4:35 PM |
| Goldman has a new favorite biotech because of potential Alzheimer's blockbuster
finance.yahoo.com - August 18 at 3:57 AM |
| Biogen Inc. (BIIB) Upgraded by Vetr Inc. to Strong-Buy
www.americanbankingnews.com - August 18 at 12:34 AM |
| Notable Thursday Option Activity: DE, NVDA, BIIB - Nasdaq
www.nasdaq.com - August 17 at 10:56 PM |
| Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List
finance.yahoo.com - August 16 at 5:06 PM |
| Steven Cohen Buys Biogen Inc, Alphabet Inc, Comcast Corp, Sells Facebook Inc, Advance Auto ...
www.nasdaq.com - August 15 at 5:23 PM |
| Biogen Inc. (BIIB) Raised to Strong-Buy at Vetr Inc.
www.americanbankingnews.com - August 11 at 12:38 AM |
| Comparing Myovant Sciences (MYOV) and Biogen (NASDAQ:BIIB)
www.americanbankingnews.com - August 10 at 10:24 PM |
| Noteworthy ETF Inflows: VHT, TMO, BIIB, AET - Nasdaq
www.nasdaq.com - August 8 at 4:18 PM |
| Biogen Inc. (BIIB) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 8 at 2:44 PM |
| Biogen Inc. (BIIB) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - August 6 at 12:42 PM |
Biogen (BIIB) Chart for Monday, September, 25, 2017
